ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

JLM019

A development code. Also written as “JLM019 Injection”.

Its studies are mostly in Hodgkin Disease, led by Jecho Biopharmaceuticals.

Furthest: phase 1, since May 18, 20261 company-led study, 1 open or runningNext primary completion: Mar 14, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jecho Biopharmaceuticals11 open or runningphase 1since May 18, 2026May 18, 2026Mar 14, 2029phase 1 · NCT07623850

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2026First study: phase 1 study in Hodgkin DiseaseFirst studyNCT07623850 · 115 planned · China

Ahead

  1. Mar 14, 2029Primary completion: phase 1 study in Hodgkin DiseaseNCT07623850

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623850Hodgkin Disease · China1RecruitingMar 14, 2029115

How it is read

Names in the registry

  • “JLM019 Injection”, 1 entry

Codes read as this program: JLM019.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.